Open Orphan (ORPH) & Angle (AGL): 2 AIM pharma stocks to buy in September

Highlights

  • AIM listed pharma companies, Open Orphan and Angel have given over 80% return in a year.
  • Open Orphan through its subsidiary hVIVO, inked an £8.1 million contract with a pharma firm.
  • Angle inked a pharma services contract with a pharma firm to develop immunofluorescence.

Pharma stocks listed on AIM present attractive investment opportunities for investors seeking to diversify their portfolios, and they simultaneously offer ample growth prospects. AIM pharma stocks comprise smaller pharmaceutical companies that desire to raise capital through listing on a public exchange.

Here we take a look at 2 AIM-listed pharma stocks that offer a high return to shareholders – Open Orphan Plc and Angle Plc.

                 

AIM Pharma Stocks to Buy in September

 

Open Orphan Plc (LON: ORPH)

Open Orphan is a specialist contract research organisation (CRO) engaged in the human clinical trial testing of vaccines and antivirals. On 24 August 2021, Open Orphan, through its subsidiary hVIVO, inked an £8.1 million contract with a pharma firm to test the inhaled human rhinovirus (hRV) antiviral product. The study is slated to commence in H1 2022. In July 2021, Open Orphan had inked a consultancy services supply contract to support Phase II trial in Onchocerciasis Disease.

For the financial year 2020, revenues of Open Orphan surged to £22 million compared to £3.54 million in 2019. The company’s cash and cash equivalents as of 31 December 2020 were £19.2 million.

Open Orphan shares traded flat at GBX 26.00 at 10:42 AM on 6 September 2021. The shares of the company gave a return of 82.07% in the last one year to shareholders, and the market cap stood at £174.42 million.

Angle Plc (LON: AGL)

Angle is a leading global liquid biopsy firm. In July 2021, Angle inked a pharma services contract with a pharma firm to develop immunofluorescence (IF) assays using its Parsortix® system that enables detection of specific protein markers expressed by circulating tumour cells (CTCs).  

For the financial year 2020, Angle recorded revenues of £0.8 million compared to £0.6 million for the eight months ended 2019. The company’s cash and cash equivalents balance stood at £28.6 million as of 31 December 2020 compared to £18.8 million in 2019.

Angle shares traded at GBX 113.50, down slightly by 0.83% at 10:45 AM on 6 September 2021. The shares of the company gave a return of 115.56% in the last one year to shareholders, and the market cap stood at £268.90 million.

Bottom Line

Successful research trials, new drug launches, and partnerships may drive the share prices of AIM listed pharma companies. Robust developments in the field of medical technology and pharma have been offering investors attractive returns. Investors keen on diversifying may choose to invest in these high return pharma stocks this month.

Comment


Disclaimer